Notably, targeting ERK in non-tumor cells has been shown to induce resistance against TRAIL, implying that an ERK inhibition/TRAIL combination would efficiently target tumor cells without harming normal cells (40). This evidence concerns the gene TNFSF10 and neoplasm.